ISRG vs LLY
ISRG: Intuitive Surgical is the dominant innovator and market leader in robotic-assisted surgical platforms, driving a shift toward minimally invasive clinical outcomes. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | ISRG | LLY | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $373.57 | $1,246.93 | |
| Market cap as of 2026-08-24 | $132.0B | $1.17T | |
| P/E as of 2026-08-24 | 42.81 | 41.85 | LLY lower |
| PEG as of 2026-08-24 | 2.42 | 1.48 | LLY lower |
| Net margin as of 2026-08-24 | +28.4% | +33.5% | LLY higher |
| Gross margin as of 2026-08-24 | +66.7% | +83.4% | LLY higher |
| Operating margin as of 2026-08-24 | +31.3% | +42.2% | LLY higher |
| ROE as of 2026-08-24 | +17.8% | +92.6% | LLY higher |
| ROA as of 2026-08-24 | +15.5% | +22.0% | LLY higher |
| Debt / equity as of 2026-08-24 | 0.00 | 1.62 | ISRG lower |
| Revenue growth (YoY) as of 2026-08-24 | +20.7% | +49.6% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +17.4% | +31.7% | LLY higher |
| Dividend yield as of 2026-08-24 | n/a | +0.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 1.16 | 0.55 | |
| 1-year return as of 2026-08-24 close | -21.5% | +75.2% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.